StockData
Anbio Biotechnology logo

Anbio Biotechnology (NNNN) income statement

NNNNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 7, 2026Score 11/30
$3.60−0.05 (-1.37%)

Close on Nov 18, 2026Market cap $518.01MP/E 24.5Yield –

Anbio Biotechnology income statement

Ratios

Latest available, balances at Dec 31, 2025

Profitability, FY2025

Gross margin
87.2%
Operating margin
66.7%
Net margin
74.1%
Return on equity, FY2025
27.0%

Financial strength

Current ratio
344.31
Debt to equity
–
Debt to assets
–
Cash to current liabilities
8842.3%

Valuation

P/E ratio
24.5
Price to sales
59.91
Price to book
17.18
Dividend yield
–

See a number that looks wrong?